Pub Date : 2025-02-03DOI: 10.1016/j.hsr.2025.100219
Neeru Bhanwala , Raunak Katiyar , Sumit Kumar , Ashok K. Datusalia , Gopal L. Khatik
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) globally. Despite significant progress in biomedical research, novel treatment strategies, and preventative measures, the incidence rates of TB continue to rise. Peucedanum ostruthium, often called masterwort, is a flowering plant from the Apiaceae family used to treat various ailments. However, the specific biochemical mechanism behind its therapeutic effect remains unidentified. The phytoconstituents of P. ostruthium were studied using Swiss Target Prediction to determine the target genes. The DisGeNET datasets were used to extract genes and variations associated with TB. Gene-gene interactions were examined using the STRING database, while gene enrichment analysis was done using the SR Plot database. P. ostruthium identified nine active constituents that have 256 potential therapeutic targets. In addition, the docking studies demonstrated that kampeferol-3-O-rutinoside exhibits stronger binding affinities to the Mycobacterial membrane protein Large 3 (MmpL3). This study presents compelling evidence that P. ostruthium may be effectively used to target TB after experimental validation. Additionally, it establishes a novel basis for additional experimental investigations into the anti-tubercular properties of P. ostruthium.
{"title":"Network pharmacology and in silico investigation into the therapeutic potential of phytoconstituents of Peucedanum ostruthium as anti-tubercular agents","authors":"Neeru Bhanwala , Raunak Katiyar , Sumit Kumar , Ashok K. Datusalia , Gopal L. Khatik","doi":"10.1016/j.hsr.2025.100219","DOIUrl":"10.1016/j.hsr.2025.100219","url":null,"abstract":"<div><div><em>Mycobacterium tuberculosis</em> is the causative agent of tuberculosis (TB) globally. Despite significant progress in biomedical research, novel treatment strategies, and preventative measures, the incidence rates of TB continue to rise. <em>Peucedanum ostruthium</em>, often called <em>masterwort</em>, is a flowering plant from the <em>Apiaceae</em> family used to treat various ailments. However, the specific biochemical mechanism behind its therapeutic effect remains unidentified. The phytoconstituents of <em>P. ostruthium</em> were studied using Swiss Target Prediction to determine the target genes. The DisGeNET datasets were used to extract genes and variations associated with TB. Gene-gene interactions were examined using the STRING database, while gene enrichment analysis was done using the SR Plot database. <em>P. ostruthium</em> identified nine active constituents that have 256 potential therapeutic targets. In addition, the docking studies demonstrated that kampeferol-3-O-rutinoside exhibits stronger binding affinities to the Mycobacterial membrane protein Large 3 (MmpL3). This study presents compelling evidence that <em>P. ostruthium</em> may be effectively used to target TB after experimental validation. Additionally, it establishes a novel basis for additional experimental investigations into the anti-tubercular properties of <em>P. ostruthium</em>.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143360677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-29DOI: 10.1016/j.hsr.2025.100217
Sebastian Ndlovu , Stanley Masunda , Emmanuel Oladeji , Ahmed Lashin , Ahmed Kaddah , Khalid A. Shah
Controversy remains with regards to the timing of surgical stabilisation of unstable thoracolumbar fractures in adult polytrauma patients. We aimed to compare early versus late fixation of thoracolumbar spine fractures focusing on length of hospital stay (HLOS), length of stay in ICU (ICULOS), respiratory complications, mortality, and long-term functional outcome measures.
Electronic database search was conducted on PubMed, Cochrane, CENTRAL, and Embase spanning 1999 to 2023 using a developed search strategy. The time cut off used to distinguish between early and late stabilisation was 72 h from injury. Statistical analysis of primary outcome data was performed with Comprehensive Meta-analysis software using the standardised difference in means as the effect size index.
2082 articles were retrieved, eighty screened by full text and a final eleven studies comprising 3874 patients deemed eligible for inclusion in this review. The overall level of evidence of included studies was low with only one prospective cohort study. A subgroup meta-analysis using a random effects model showed that early fixation of unstable thoracolumbar spinal fractures leads to a statistically significant decrease in HLOS compared to late fixation with a mean effect size of -0.502. Early fixation was also associated with reduced ICULOS and respiratory complications.
Early surgical stabilisation of unstable thoracolumbar spine fractures within 72h of injury is safe and associated with favorable short-term outcomes in adult polytrauma patients with unstable thoracolumbar spine fractures. Further high-level prospective studies are recommended to investigate whether the short-term gains shown can translate to superior long-term functional outcomes.
{"title":"Early versus late surgical stabilisation of unstable thoracolumbar spine fractures in adult polytrauma patients: A systematic review and meta-analysis","authors":"Sebastian Ndlovu , Stanley Masunda , Emmanuel Oladeji , Ahmed Lashin , Ahmed Kaddah , Khalid A. Shah","doi":"10.1016/j.hsr.2025.100217","DOIUrl":"10.1016/j.hsr.2025.100217","url":null,"abstract":"<div><div>Controversy remains with regards to the timing of surgical stabilisation of unstable thoracolumbar fractures in adult polytrauma patients. We aimed to compare early versus late fixation of thoracolumbar spine fractures focusing on length of hospital stay (HLOS), length of stay in ICU (ICULOS), respiratory complications, mortality, and long-term functional outcome measures.</div><div>Electronic database search was conducted on PubMed, Cochrane, CENTRAL, and Embase spanning 1999 to 2023 using a developed search strategy. The time cut off used to distinguish between early and late stabilisation was 72 h from injury. Statistical analysis of primary outcome data was performed with Comprehensive Meta-analysis software using the standardised difference in means as the effect size index.</div><div>2082 articles were retrieved, eighty screened by full text and a final eleven studies comprising 3874 patients deemed eligible for inclusion in this review. The overall level of evidence of included studies was low with only one prospective cohort study. A subgroup meta-analysis using a random effects model showed that early fixation of unstable thoracolumbar spinal fractures leads to a statistically significant decrease in HLOS compared to late fixation with a mean effect size of -0.502. Early fixation was also associated with reduced ICULOS and respiratory complications.</div><div>Early surgical stabilisation of unstable thoracolumbar spine fractures within 72h of injury is safe and associated with favorable short-term outcomes in adult polytrauma patients with unstable thoracolumbar spine fractures. Further high-level prospective studies are recommended to investigate whether the short-term gains shown can translate to superior long-term functional outcomes.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143340813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-27DOI: 10.1016/j.hsr.2025.100215
JC Baudrexl , K Mosetter , R Mosetter , D Gagiannis
Chronic pain conditions, mental illnesses and, more recently, post-COVID syndrome are still difficult to treat satisfactorily in many cases, despite rapid medical progress. New, highly individualised treatment approaches are required to alleviate and ideally even cure complaints that are relevant to everyday life. Myoreflex therapy is a new type of therapeutic procedure that has been developed since the early 1980s on the basis of various findings and sciences, but has so far only been sparsely described in the international literature. The aim of this paper is to provide an overview of the findings to date and to categorise the therapy within the current therapeutic landscape. For this purpose, a comprehensive literature search was conducted in MEDLINE/Pubmed, Google Scholar and the Cochrane database. In addition, the most important data from the basic works on the initial description of myoreflex therapy were extracted and summarised in condensed form. In this way, the significance of myoreflex therapy as a new, integrative and holistically orientated form of therapy can be demonstrated. It represents a neurophysiologically based further development of osteopathy, acupressure and concentrative movement therapy and utilises neuronal control circuits to additionally tense defined muscle groups in order to stimulate self-regulation and reduce pain. By combining various established therapeutic principles in this new method, chronic pain conditions, psychologically induced musculoskeletal changes and non-specific post-acute COVID symptoms can be treated much more effectively.
{"title":"Introducing the “Gamechanger“ - Myoreflextherapy","authors":"JC Baudrexl , K Mosetter , R Mosetter , D Gagiannis","doi":"10.1016/j.hsr.2025.100215","DOIUrl":"10.1016/j.hsr.2025.100215","url":null,"abstract":"<div><div>Chronic pain conditions, mental illnesses and, more recently, post-COVID syndrome are still difficult to treat satisfactorily in many cases, despite rapid medical progress. New, highly individualised treatment approaches are required to alleviate and ideally even cure complaints that are relevant to everyday life. Myoreflex therapy is a new type of therapeutic procedure that has been developed since the early 1980s on the basis of various findings and sciences, but has so far only been sparsely described in the international literature. The aim of this paper is to provide an overview of the findings to date and to categorise the therapy within the current therapeutic landscape. For this purpose, a comprehensive literature search was conducted in MEDLINE/Pubmed, Google Scholar and the Cochrane database. In addition, the most important data from the basic works on the initial description of myoreflex therapy were extracted and summarised in condensed form. In this way, the significance of myoreflex therapy as a new, integrative and holistically orientated form of therapy can be demonstrated. It represents a neurophysiologically based further development of osteopathy, acupressure and concentrative movement therapy and utilises neuronal control circuits to additionally tense defined muscle groups in order to stimulate self-regulation and reduce pain. By combining various established therapeutic principles in this new method, chronic pain conditions, psychologically induced musculoskeletal changes and non-specific post-acute COVID symptoms can be treated much more effectively.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-27DOI: 10.1016/j.hsr.2025.100218
Ahmed N. Al-Jamal , Ali Fawzi Al-Hussainy , Bahira Abdulrazzaq Mohammed , Hadi Hussein Abbas , Issa Mohammed Kadhim , Zahraa Hassan Ward , Debarshi Kar Mahapatra , Tomy Muringayil Joseph , Ehsan kianfar , Sabu Thomas
One approach to treating cancer and other infections is Photodynamic Therapy (PDT). Numerous treatment modalities including PDT have long recognized the need to improve the performance of nanoscale therapeutic frameworks. Photosensitizers (Ps) are NPs used in PDT, selectively targeting malignant tissues for therapeutic effects, while sparing healthy cells. Using NPs as a carrier might be a great achievement since these NPs have all the necessary components for an ideal PDT operator. The review explores various types of NPs used in PDT. It also depicts the subsequent advancements in the use of inorganic NPs and NPs derived from biodegradable polymers. Varieties of dynamic NPs including those that upconvert, self-radiate, and photosynthesize are now under review.
{"title":"Photodynamic Therapy (PDT) in drug delivery: Nano-innovations enhancing treatment outcomes","authors":"Ahmed N. Al-Jamal , Ali Fawzi Al-Hussainy , Bahira Abdulrazzaq Mohammed , Hadi Hussein Abbas , Issa Mohammed Kadhim , Zahraa Hassan Ward , Debarshi Kar Mahapatra , Tomy Muringayil Joseph , Ehsan kianfar , Sabu Thomas","doi":"10.1016/j.hsr.2025.100218","DOIUrl":"10.1016/j.hsr.2025.100218","url":null,"abstract":"<div><div>One approach to treating cancer and other infections is Photodynamic Therapy (PDT). Numerous treatment modalities including PDT have long recognized the need to improve the performance of nanoscale therapeutic frameworks. Photosensitizers (Ps) are NPs used in PDT, selectively targeting malignant tissues for therapeutic effects, while sparing healthy cells. Using NPs as a carrier might be a great achievement since these NPs have all the necessary components for an ideal PDT operator. The review explores various types of NPs used in PDT. It also depicts the subsequent advancements in the use of inorganic NPs and NPs derived from biodegradable polymers. Varieties of dynamic NPs including those that upconvert, self-radiate, and photosynthesize are now under review.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143158066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-27DOI: 10.1016/j.hsr.2025.100216
Gunjan Joshi , Tanisha Rathore , Kedarmal Verma
This paper provides a comprehensive review of academic research pertaining to the interaction of emotions and false memory, elucidating the malleable nature of human memories. False memories can have serious effects in forensic and clinical settings, like misremembering events or making up events. In these contexts, the influence of emotions and misinformation can frequently lead to distortions in memory. The presence of intense emotional experiences within these environments, combined with the presence of multiple sources of deceptive information, increases the likelihood of the formation of false memories induced by suggestion. Clinically, understanding these dynamics is crucial for developing therapeutic interventions to mitigate the impact of false memories on individuals' mental health. This review paper delves into the intricate relationship between emotions and false memory, examining two primary paradigms: the Deese-Roediger-McDermott (DRM) and misinformation paradigms. The paper comprehensively synthesizes existing research, revealing that emotions significantly influence the generation and retrieval of false memories. Findings indicate that mood states and emotional content play pivotal roles in shaping memory distortions. In the DRM paradigm, negative mood tends to reduce false memory formation, while positive mood can amplify it. Emotional valence also impacts false recollections, with negative content often associated with increased false memories. In the misinformation paradigm, mood is impacting the confidence attributed to false recollections rather than affecting susceptibility to misinformation. When comparing emotional content, negative events are leading to induce more false memories due to their ease of recalling negative gist and semantic connections. Both the DRM and misinformation paradigms offer valuable insights into the underlying mechanisms of emotional false memory. The paper discusses the implications of these findings for various fields, such as forensic psychology and clinical settings, and highlights the need for further research to elucidate the complex interplay between emotions and memory.
{"title":"Emotion-Induced Memory Distortions: Insights from Deese-Roediger-McDermott and Misinformation Paradigms—A Comprehensive Review","authors":"Gunjan Joshi , Tanisha Rathore , Kedarmal Verma","doi":"10.1016/j.hsr.2025.100216","DOIUrl":"10.1016/j.hsr.2025.100216","url":null,"abstract":"<div><div>This paper provides a comprehensive review of academic research pertaining to the interaction of emotions and false memory, elucidating the malleable nature of human memories. False memories can have serious effects in forensic and clinical settings, like misremembering events or making up events. In these contexts, the influence of emotions and misinformation can frequently lead to distortions in memory. The presence of intense emotional experiences within these environments, combined with the presence of multiple sources of deceptive information, increases the likelihood of the formation of false memories induced by suggestion. Clinically, understanding these dynamics is crucial for developing therapeutic interventions to mitigate the impact of false memories on individuals' mental health. This review paper delves into the intricate relationship between emotions and false memory, examining two primary paradigms: the Deese-Roediger-McDermott (DRM) and misinformation paradigms. The paper comprehensively synthesizes existing research, revealing that emotions significantly influence the generation and retrieval of false memories. Findings indicate that mood states and emotional content play pivotal roles in shaping memory distortions. In the DRM paradigm, negative mood tends to reduce false memory formation, while positive mood can amplify it. Emotional valence also impacts false recollections, with negative content often associated with increased false memories. In the misinformation paradigm, mood is impacting the confidence attributed to false recollections rather than affecting susceptibility to misinformation. When comparing emotional content, negative events are leading to induce more false memories due to their ease of recalling negative gist and semantic connections. Both the DRM and misinformation paradigms offer valuable insights into the underlying mechanisms of emotional false memory. The paper discusses the implications of these findings for various fields, such as forensic psychology and clinical settings, and highlights the need for further research to elucidate the complex interplay between emotions and memory.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-23DOI: 10.1016/j.hsr.2025.100213
Darshan Kumar R, Richa Sood, Prashant Tiwari
Melasma is a prevalent acquired hyperpigmentation disorder characterized by irregular brownish patches on areas of the skin frequently exposed to sunlight. Although benign, it can significantly affect an individual's quality of life due to limited treatment options. Over the years, various therapeutic approaches, including topical agents, chemical peels, laser treatments, and oral medications, have been explored. However, managing melasma remains challenging, with high recurrence rates and inconsistent therapeutic outcomes. This review focuses on recent methodological advancements in elucidating the pathophysiology of melasma and the development of novel treatment strategies. Research leveraging histological analyses, genetic profiling, and biochemical assays has elucidated novel therapeutic targets, including oxidative stress pathways and inflammatory mediators. Advances in topical formulations, such as combination therapies containing tyrosinase inhibitors, antioxidants, and anti-inflammatory agents, have shown promising results in improving pigmentation and preventing recurrence. Furthermore, targeted delivery systems, such as nanoparticles and liposomes, have enhanced the efficacy and penetration of active ingredients, leading to better clinical outcomes.
In addition to topical treatments, recent studies have highlighted the efficacy of emerging modalities such as fractional lasers, intense pulsed light (IPL), and microneedling in the management of melasma. These techniques offer precise targeting of melanin without causing significant epidermal damage, thus minimizing the risk of post-inflammatory hyperpigmentation. Moreover, advances in oral medications have shown encouraging results in reducing melanin production and preventing melasma recurrence.
In conclusion, current advances in melasma management provide great opportunities for improving outcomes and increasing patient satisfaction. A multidisciplinary approach integrating dermatologists, cosmetic surgeons, and skincare professionals is essential for designing comprehensive and individualized treatment regimens. These advancements underscore the potential for improving patient outcomes and satisfaction while emphasizing the need for robust research to optimize therapeutic strategies.
{"title":"Melasma management: Unveiling recent breakthroughs through literature analysis","authors":"Darshan Kumar R, Richa Sood, Prashant Tiwari","doi":"10.1016/j.hsr.2025.100213","DOIUrl":"10.1016/j.hsr.2025.100213","url":null,"abstract":"<div><div>Melasma is a prevalent acquired hyperpigmentation disorder characterized by irregular brownish patches on areas of the skin frequently exposed to sunlight. Although benign, it can significantly affect an individual's quality of life due to limited treatment options. Over the years, various therapeutic approaches, including topical agents, chemical peels, laser treatments, and oral medications, have been explored. However, managing melasma remains challenging, with high recurrence rates and inconsistent therapeutic outcomes. This review focuses on recent methodological advancements in elucidating the pathophysiology of melasma and the development of novel treatment strategies. Research leveraging histological analyses, genetic profiling, and biochemical assays has elucidated novel therapeutic targets, including oxidative stress pathways and inflammatory mediators. Advances in topical formulations, such as combination therapies containing tyrosinase inhibitors, antioxidants, and anti-inflammatory agents, have shown promising results in improving pigmentation and preventing recurrence. Furthermore, targeted delivery systems, such as nanoparticles and liposomes, have enhanced the efficacy and penetration of active ingredients, leading to better clinical outcomes.</div><div>In addition to topical treatments, recent studies have highlighted the efficacy of emerging modalities such as fractional lasers, intense pulsed light (IPL), and microneedling in the management of melasma. These techniques offer precise targeting of melanin without causing significant epidermal damage, thus minimizing the risk of post-inflammatory hyperpigmentation. Moreover, advances in oral medications have shown encouraging results in reducing melanin production and preventing melasma recurrence.</div><div>In conclusion, current advances in melasma management provide great opportunities for improving outcomes and increasing patient satisfaction. A multidisciplinary approach integrating dermatologists, cosmetic surgeons, and skincare professionals is essential for designing comprehensive and individualized treatment regimens. These advancements underscore the potential for improving patient outcomes and satisfaction while emphasizing the need for robust research to optimize therapeutic strategies.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The healthcare sector is intricate, generating vast amounts of data from various sources at an accelerated pace. The contemporary trend of Big Data Analytics is pivotal, impacting not only the pharmaceutical industry but also transforming healthcare, contributing to personalized treatment, aiding in preventive healthcare, managing electronic health records, facilitating adverse drug reporting, and incorporating consumer reviews. This article provides an overview of the inevitable influence of big data and the utilization of artificial intelligence in revolutionizing both healthcare and the pharmaceutical sector. It delves into the notable benefits and challenges encountered in advancing data analytics of the early 21st century.In many countries, Post-marketing surveillance of drug safety relinquishes on a systematic analysis of spontaneous using Generative artificial intelligence (AI) to overcome gaps in the present PV ecosystem is critical to maintaining an uninterrupted record of security and effectiveness within healthcare analytics, data mining techniques, predictive analytics, and the emergence of scientific fields like bioinformatics and health informatics are empowered by Big Data. Nevertheless, the integration of AI in healthcare, especially in pharmacovigilance, aligns with the evolving landscape of electronic health information technology. In conclusion, review highlights the transformative impact of Big Data and AI in healthcare, emphasizing their applications in pharmacovigilance and pharmacoepidemiology. The continuous evolution of these technologies holds promise for improving patient safety, personalized medicine, and overall healthcare outcomes.
{"title":"Beyond boundaries: Charting the frontier of healthcare with big data and ai advancements in pharmacovigilance","authors":"Arohi Agarwal , Gagan Singh , Samyak Jain , Piyush Mittal","doi":"10.1016/j.hsr.2025.100214","DOIUrl":"10.1016/j.hsr.2025.100214","url":null,"abstract":"<div><div>The healthcare sector is intricate, generating vast amounts of data from various sources at an accelerated pace. The contemporary trend of Big Data Analytics is pivotal, impacting not only the pharmaceutical industry but also transforming healthcare, contributing to personalized treatment, aiding in preventive healthcare, managing electronic health records, facilitating adverse drug reporting, and incorporating consumer reviews. This article provides an overview of the inevitable influence of big data and the utilization of artificial intelligence in revolutionizing both healthcare and the pharmaceutical sector. It delves into the notable benefits and challenges encountered in advancing data analytics of the early 21st century.In many countries, Post-marketing surveillance of drug safety relinquishes on a systematic analysis of spontaneous using Generative artificial intelligence (AI) to overcome gaps in the present PV ecosystem is critical to maintaining an uninterrupted record of security and effectiveness within healthcare analytics, data mining techniques, predictive analytics, and the emergence of scientific fields like bioinformatics and health informatics are empowered by Big Data. Nevertheless, the integration of AI in healthcare, especially in pharmacovigilance, aligns with the evolving landscape of electronic health information technology. In conclusion, review highlights the transformative impact of Big Data and AI in healthcare, emphasizing their applications in pharmacovigilance and pharmacoepidemiology. The continuous evolution of these technologies holds promise for improving patient safety, personalized medicine, and overall healthcare outcomes.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100214"},"PeriodicalIF":0.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-11DOI: 10.1016/j.hsr.2025.100212
P. Rastgoo Oskoui, M. Rezvani
Recent advances in nanotechnology have made magnetic fluid hyperthermia a potential therapeutic platform for cancer treatment. Magnetic fluid hyperthermia can be used alone or in combination with other conventional therapeutic methods such as chemotherapy, radiotherapy, etc. In order to accurately control the temperature of cancerous tissue and prevent cell necrosis, it is necessary to identify and optimize the factors affecting the magnetic losses of nanoparticles. The type of nanoparticles, the size and shape of the particles, the type of solution used for dispersion, etc. are some of the factors that affect the rate of heat loss under alternating magnetic fields. In this review, the effect of various factors on the rate of heat generation has been briefly reviewed. Also, smart drug delivery systems based on drug release during temperature increase due to magnetic losses were investigated.
{"title":"Revolution in cancer treatment methods: Perspective review of factors affecting the final results of nanoparticles used in magnetic fluid hyperthermia","authors":"P. Rastgoo Oskoui, M. Rezvani","doi":"10.1016/j.hsr.2025.100212","DOIUrl":"10.1016/j.hsr.2025.100212","url":null,"abstract":"<div><div>Recent advances in nanotechnology have made magnetic fluid hyperthermia a potential therapeutic platform for cancer treatment. Magnetic fluid hyperthermia can be used alone or in combination with other conventional therapeutic methods such as chemotherapy, radiotherapy, etc. In order to accurately control the temperature of cancerous tissue and prevent cell necrosis, it is necessary to identify and optimize the factors affecting the magnetic losses of nanoparticles. The type of nanoparticles, the size and shape of the particles, the type of solution used for dispersion, etc. are some of the factors that affect the rate of heat loss under alternating magnetic fields. In this review, the effect of various factors on the rate of heat generation has been briefly reviewed. Also, smart drug delivery systems based on drug release during temperature increase due to magnetic losses were investigated.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100212"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-11DOI: 10.1016/j.hsr.2025.100211
John S. Bolwell
Deaths and serious injuries caused by medical errors continue to beset the healthcare systems of all developed countries. Most are due to failures in the processes of care exacerbated by poor communication between healthcare providers and with patients, particularly the elderly with varying degrees of cognitive impairment. The global phenomenon of aging populations due to declining birthrates and increased life expectancy may have detrimental consequences for societies and is briefly considered. The most common medical errors are failure to diagnose, misdiagnoses, failure to treat, surgical and anesthetic errors, negligent postoperative care, medication errors, failure to order, or act on, laboratory tests, and birth injuries (mother and baby). Estimated numbers of deaths vary widely, for example 22,000 to 40,000 in the UK and 98,000 to 251,000 in the US which attests to the complexity of accurate quantification. Regardless of the true magnitude there is no doubt that several deaths due to preventable medical errors occur in each hospital every year and there are 1,148 public and private hospitals in the UK and 6,120 in the US. The history and efficacy of preventative measures such as continuing professional development, continuity of care, multi-disciplinary-team management and quality assurance programs are summarized. The UK and the US have worse healthcare outcomes and shorter average life expectancies than comparable developed countries and these issues are discussed. Reforms which might contribute to the delivery of safe, universal and sustainable healthcare in the UK and the US are reviewed.
{"title":"A Review of Healthcare Challenges in the UK and the US: Medical Errors, Aging, Private Healthcare and Governance","authors":"John S. Bolwell","doi":"10.1016/j.hsr.2025.100211","DOIUrl":"10.1016/j.hsr.2025.100211","url":null,"abstract":"<div><div>Deaths and serious injuries caused by medical errors continue to beset the healthcare systems of all developed countries. Most are due to failures in the processes of care exacerbated by poor communication between healthcare providers and with patients, particularly the elderly with varying degrees of cognitive impairment. The global phenomenon of aging populations due to declining birthrates and increased life expectancy may have detrimental consequences for societies and is briefly considered. The most common medical errors are failure to diagnose, misdiagnoses, failure to treat, surgical and anesthetic errors, negligent postoperative care, medication errors, failure to order, or act on, laboratory tests, and birth injuries (mother and baby). Estimated numbers of deaths vary widely, for example 22,000 to 40,000 in the UK and 98,000 to 251,000 in the US which attests to the complexity of accurate quantification. Regardless of the true magnitude there is no doubt that several deaths due to preventable medical errors occur in each hospital every year and there are 1,148 public and private hospitals in the UK and 6,120 in the US. The history and efficacy of preventative measures such as continuing professional development, continuity of care, multi-disciplinary-team management and quality assurance programs are summarized. The UK and the US have worse healthcare outcomes and shorter average life expectancies than comparable developed countries and these issues are discussed. Reforms which might contribute to the delivery of safe, universal and sustainable healthcare in the UK and the US are reviewed.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes mellitus (DM) is a chronic condition that lowers life expectancy and quality of life when left untreated or improperly managed. Infections, both common and pathogenic, such as emphysematous pyelonephritis, malignant otitis externa, mucormycosis, and Fournier's gangrene, are more common in diabetic patients. Because patients with diabetes have a lower prognosis and more frequent Urinary tract infections (UTIs) than those without diabetes. Based on the literature, we carried out a review study that examined the characteristics of the prevalence of UTIs among diabetic patients in various countries over time, as well as the associated risk factors, processes, and therapeutic issues. The results show that compared to people without diabetes, diabetic patients with UTIs have higher rates of hospitalization, recurrence, and mortality, as well as a more frequent evolution to bacteremia. Pregnancy, advanced age, multidrug-resistant bacteria, and the length of a patient's diabetes seem to be the potential risk factors that have been found. With rare exceptions, the antibiotic susceptibility profile and bacterial strains responsible for UTIs in patients with DM are similar to those in non-diabetics; nonetheless, careful selection of antimicrobial agents, and treatment duration should match that needed for complicated UTIs.
{"title":"Combatting multi-drug resistance in urinary tract infections among diabetic populations: A perspective review","authors":"Rahima Tanbin Tama , Md. Sakhawat Hossain , Md. Shahidul Islam , Rifaia Sultana Chowdhury , Md. Ashikur Rahaman , Md. Ashraful Alam","doi":"10.1016/j.hsr.2025.100209","DOIUrl":"10.1016/j.hsr.2025.100209","url":null,"abstract":"<div><div>Diabetes mellitus (DM) is a chronic condition that lowers life expectancy and quality of life when left untreated or improperly managed. Infections, both common and pathogenic, such as emphysematous pyelonephritis, malignant otitis externa, mucormycosis, and Fournier's gangrene, are more common in diabetic patients. Because patients with diabetes have a lower prognosis and more frequent Urinary tract infections (UTIs) than those without diabetes. Based on the literature, we carried out a review study that examined the characteristics of the prevalence of UTIs among diabetic patients in various countries over time, as well as the associated risk factors, processes, and therapeutic issues. The results show that compared to people without diabetes, diabetic patients with UTIs have higher rates of hospitalization, recurrence, and mortality, as well as a more frequent evolution to bacteremia. Pregnancy, advanced age, multidrug-resistant bacteria, and the length of a patient's diabetes seem to be the potential risk factors that have been found. With rare exceptions, the antibiotic susceptibility profile and bacterial strains responsible for UTIs in patients with DM are similar to those in non-diabetics; nonetheless, careful selection of antimicrobial agents, and treatment duration should match that needed for complicated UTIs.</div></div>","PeriodicalId":73214,"journal":{"name":"Health sciences review (Oxford, England)","volume":"14 ","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号